NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NK
CUSIPN/A
Phone858-633-0300
Debt
Debt-to-Equity Ratio0.01
Current Ratio6.54
Quick Ratio6.54
Price-To-Earnings
Trailing P/E Ratio-2.28
Forward P/E Ratio-1.77
P/E GrowthN/A
Sales & Book Value
Annual Sales$50,000.00
Price / Sales4,263.71
Cash FlowN/A
Price / CashN/A
Book Value$2.75 per share
Price / Book0.99
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-96,420,000.00
Net Margins-254,940.98%
Return on Equity-43.71%
Return on Assets-37.53%
Miscellaneous
Employees139
Outstanding Shares78,090,000
Nantkwest (NASDAQ:NK) Frequently Asked Questions
What is Nantkwest's stock symbol?
Nantkwest trades on the NASDAQ under the ticker symbol "NK."
How were Nantkwest's earnings last quarter?
Nantkwest Inc (NASDAQ:NK) posted its quarterly earnings results on Monday, August, 15th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.06. The biotechnology company earned $0.01 million during the quarter, compared to analysts' expectations of $0.10 million. Nantkwest had a negative return on equity of 43.71% and a negative net margin of 254,940.98%. View Nantkwest's Earnings History.
What price target have analysts set for NK?
2 analysts have issued 1 year target prices for Nantkwest's stock. Their forecasts range from $3.00 to $3.00. On average, they expect Nantkwest's stock price to reach $3.00 in the next year. View Analyst Ratings for Nantkwest.
Who are some of Nantkwest's key competitors?
Some companies that are related to Nantkwest include Coherus Biosciences (CHRS), Heska (HSKA), La Jolla Pharmaceutical (LJPC), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Mesoblast (MESO), Scholar Rock (SRRK), CASI Pharmaceuticals (CASI), Vericel (VCEL), Surface Oncology (SURF), Nightstar Therapeutics (NITE), MeiraGTx (MGTX) and PDL BioPharma (PDLI).
Who are Nantkwest's key executives?
Nantkwest's management team includes the folowing people:
- Dr. Patrick Soon-Shiong FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 65)
- Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 53)
- Mr. Richard J. Tajak, Chief Financial Officer (Age 65)
- Ms. Sonja Nelson, Chief Accounting Officer (Age 45)
- Mr. David J. Pyrce M.B.A., Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 61)
When did Nantkwest IPO?
(NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.
Has Nantkwest been receiving favorable news coverage?
Media headlines about NK stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nantkwest earned a daily sentiment score of 0.14 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.91 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Nantkwest's major shareholders?
Nantkwest's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.27%), Millennium Management LLC (0.20%), Alps Advisors Inc. (0.13%), JPMorgan Chase & Co. (0.06%), DekaBank Deutsche Girozentrale (0.04%) and A.R.T. Advisors LLC (0.04%). Company insiders that own Nantkwest stock include Barry J Simon, John C Thomas and Steve Gorlin. View Institutional Ownership Trends for Nantkwest.
Which institutional investors are selling Nantkwest stock?
Which institutional investors are buying Nantkwest stock?
NK stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, A.R.T. Advisors LLC, Alps Advisors Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for Nantkwest.
How do I buy shares of Nantkwest?
Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nantkwest's stock price today?
One share of NK stock can currently be purchased for approximately $2.73.
How big of a company is Nantkwest?
Nantkwest has a market capitalization of $238.17 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,420,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Nantkwest employs 139 workers across the globe.
How can I contact Nantkwest?
Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]
MarketBeat Community Rating for Nantkwest (NK)
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
